Miracor Medical Systems


Contact Ludwig Gold
Title CEO


Miracor Medical Systems has developed a unique and potentially disruptive technology, PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion), for acute coronary syndrome (ACS) and – at a later stage – heart failure patients.
The technology is based on the intermittent occlusion of the coronary sinus that empties the majority of the blood from the heart tissue (‘myocardium’). The mode of action is well-documented and has been developed over decades in cardiovascular applications such as retrograde coronary sinus cardioplegia in cardiac surgery. Miracor is now applying this knowledge for severe heart attack patients in interventional cardiology.

Company News

Miracor Medical Raises €24M in Funding

DateSep 2, 2020
Miracor Medical SA, an Awans, Belgium-based provider of innovative solutions for the treatment of severe cardiac diseases, closed a €24M Series E round of financing.
Read More →

Miracor closes $30m Series D

DateJan 4, 2018
Miracor Medical Systems said today it closed a $30.2 million (EU €25 million) round of funding as part of Series D financing round with funds slated to support further development and commercialization of its PiCSO impulse system, and announced it is moving its headquarters from Austria to Belgium.

Miracor Medical is highlighted at TCT 2015 in San Francisco

DateOct 29, 2015
Miracor’s PiCSO® Impulse System highlighted as novel therapy for Cardioprotected PCI at TCT 2015 in San Francisco. TCT (Transcatheter Cardiovascular Therapeutics) is the world’s largest educational meeting specializing in interventional cardiovascular medicine and was held by the Cardiovascular Research Foundation.